The Application of Blockchain in the Pharmaceutical Sector

The Pharmaceutical industry is vast, and within it there are many regulations that must be met to satisfy regulatory bodies, ensure a product is safe, and allow it to be sold. These regulations control all aspects of the production of a drug, including, for example, clinical trials, manufacturing, and distribution (Lo, 2017). Blockchain offers solutions to increase the validity, reliability, and efficiency of drug production by easily ensuring regulations are being met. Furthermore, it also offers the opportunity to tackle one of the biggest problems: the influx of counterfeit drugs entering the supply chain and reaching patients (Roberts, 2017).

What is blockchain?
Blockchain is a digital decentralised public ledger that is used to log transactions into ‘blocks’ in chronological order (Kacina et al., 2017; Lo, 2017). When a transaction occurs between two parties it is recorded on the blockchain and cannot be altered without changing all the blocks that follow, which cannot be done due to the decentralised nature of blockchain. The transactions occur peer to peer, removing the requirement to involve a trusted third party (Halbleib, 2017). The data on the blockchain is stored across its network of computers, therefore there is no centralised entry point which removes the risk of hacking. All the users of the network can see entries on public blockchains (Lo, 2017). Therefore, blockchain is tamper proof, reliable, and transparent, which can provide great benefits to the pharmaceutical industry.

Pharmaceutical Regulatory Issues
There are impending regulation changes within the pharmaceutical industry that, when introduced, must be adhered to. These changes are being implemented by governments worldwide with the aim of decreasing the number of counterfeit pharmaceuticals on the market (Lo, 2017). The Falsified Medicines Directive specifies that pharmaceutical products must be serialised so they can be tracked by February 2019, in the European Union. Similarly, the Drug Supply Chain Security Act was introduced in the US in 2013 by the FDA. This is like the Falsified Medicines Directive, stipulating that by 2023 there must be an electronic system tracking certain drugs through the supply chain in the United States (FDA, 2017; Lo, 2017).

With these upcoming regulations, all companies that operate within the supply chain are looking for ways to adhere to these guidelines and improve the security and traceability of the supply chain. Blockchain is a large part of the improvement discussion. Leveraging blockchain technology to provide full transparency and immutability throughout the supply chain may be the solution (Bocek et al, 2017; Lo, 2017).

Pharmaceutical Supply chain
The drug supply chain is a very complicated process involving many transactions, and adhering to strict regulations is of upmost importance. Currently, manufacturers have little transparency of the supply chain process to track authenticity (Sandner, 2017). Blockchain provides the means to transform the supply chain in two ways. Firstly, it can harness the Internet of Things (IoT) using smart contracts to improve the security, efficiency and reliability of the supply chain. Secondly, as a product of this, it can tackle the large problem of stolen or counterfeit pills entering the supply chain and reaching patients (Roberts, 2017).

Smart contracts are contracts that are self-executing, verifying their correctness in relation to a set of predefined rules. These rules will be set in accordance to good distribution practice (GDP) regulations. Smart contracts utilise blockchain technology to run independently and be decentralised (Bocek et al, 2017). For example, there are strict regulations controlling the distribution practices of environment sensitive pharmaceuticals (Bishara, 2006). Sensors can be implemented which monitor the temperature of each package during transport. The data recorded by the sensors will be transferred to the blockchain where smart contracts assess the temperature according to the predefined rules set in line with GDP regulations. Therefore, it can be ensured GDP regulations are met by self-executing smart contracts, reducing the number of intermediaries required, therefore reducing the costs and possible data manipulation chances (Bocek et al, 2017).

The World Health Organisation (WHO, 2010) estimated a worldwide increase of counterfeit medicine sales by 90% in five years, with a worldwide sale estimate of $75 Billion in 2010. It is clear that this is a problem, with useless or potentially harmful products reaching consumers that may require lifesaving medication. The counterfeit drug problem is particularly an issue in developing countries due to the costs of legitimate drugs being too high. It is estimated 10-30% of the drugs sold in many developing countries are counterfeit (WHO, 2010; Sandner, 2017; Lo, 2017).  The complexity of the pharmaceutical supply chain is due to the amount of times the drugs change ownership before reaching the customer. Manufacturers and customers alike are unable to verify the authenticity of the finished product when it reaches the customer due to the lack of transparency (Sandner, 2017). The blockchain solution to this issue works together with the GDP regulation adherence previously outlined. The blockchain would enable consumers to track the path of their product throughout the entire supply chain and therefore verify its authenticity. This would be made possible by packages being logged every time they change hands. A barcode would be scanned which would enter the transaction onto the immutable blockchain. A product could be therefore scanned at any time by a customer or a producer to view the entire distribution history on the blockchain. It is fully transparent and cannot be changed, and all inputs will only be possible by trusted parties (Sandner, 2017). Another benefit of the system is that if there is disruption in a part of the supply chain, the public ledger of the blockchain provides an efficient and reliable means to track where the issue arose and who was in possession of the shipment at the time (Roberts, 2017).

Clinical Trials
Currently, the credibility of the outcome from clinical trials is degraded due to a number of issues. For example, Rabah (2017) states that an estimated 50% of clinical trials are not reported, and it is not uncommon for selective data publication to take place (Nugent et al., 2016). The WHO and MHRA have tried to introduce legislation enforcing sharing of trial methodology and results, however there are no current solutions found that will effectively enforce these rules. Smart contracts operating on the blockchain could be introduced to act as unbiased and trusted administrators, which would provide transparent results from clinical trials which are fully immutable (Nugent et al., 2016). With this in place, the results from the trial would be automatically recorded to the blockchain, where they cannot be altered. This would eradicate any issues that arise from data management and presentation from trials. As a result, implementing a blockchain system would allow medical professionals to be better informed and make decisions based on increase trust due to the credibility of the trials (Nugent et al., 2016).

Additional possible applications
In research and development, information asymmetry is common between firms and investors, which prevents investors from making well informed decisions and increases uncertainty (Sandner, 2017). In the research and development stage, the funding is very important. Currently, Schöner (2017) estimates information asymmetry is potentially leading to abnormal returns of 4-6% annually in the pharmaceutical sector, which can negatively affect funding opportunities. Blockchain provides the opportunity to provide early investors increased information access with more transparency (Zhong et al, 2007; Sandner, 2017).

In the pharmaceutical industry, there can be sensitive documents that must be held by a third party, but the third party is not able to access these documents. Blockchain can facilitate this process with advanced encryption, ensuring the information held by the third party securely (Kacina et al., 2017).

Blockchain can provide multiple improvements to various aspects of the pharmaceutical industry. Presently, the integration of blockchain into the supply chain would be the most beneficial. It would ensure upcoming regulations could be met, increase the transparency of the supply chain, reduce cost over time by simplifying the process, and tackle the large issue of counterfeit pharmaceuticals. On top of this, blockchain can be used to increase the transparency in clinical trials, research and development and third-party document management.

Alex Aves


Bishara, R.H. (2006), “Cold chain management – an essential component of the global pharmaceutical supply chain”, American Pharmaceutical Review, available at: www.

FDA (2017). Drug Supply Chain Security Act (DSCSA). [online] Available at: DrugSupplyChainSecurityAct/ [Accessed 31 Jan. 2018].

Halbleib, K. (2017). Block Chain Technology and the Pharmaceutical Industry – A good fit?. [online] Kvalito Consulting Group. Available at: [Accessed 26 Jan. 2018].

Kacina, J., Harler, M., Rajnic, M. and Team of SophiaTX (2017). SophiaTX Whitepaper – The Blockchain for Business. [online] Available at: [Accessed 26 Jan. 2018].

Lo, C. (2017). [online] Pharmaceutical Technology. Available at: http://Blockchain in pharma: opportunities in the supply chain [Accessed 26 Jan. 2018].

Nugent, T., Upton, D. and Cimpoesu, M. (2016). Improving data transparency in clinical trials using blockchain smart contracts.

Rabah, K. (2017). Challenges & Opportunities for Blockchain Powered Healthcare Systems: A Review. Mara Research Journal of Medicine and Health Sciences, 1(1), pp.45-52.

Roberts, J. (2017). Big Pharma Turns to Blockchain to Track Meds. [online] Fortune. Available at: [Accessed 26 Jan. 2018].

Sandner, P. (2017). Blockchain Technology in the Pharmaceutical Industry. [online] Medium. Available at: [Accessed 30 Jan. 2018].

Schöner, M., 2017. Abnormal Returns in the Pharmaceutical Industry.

Zhong, X. and Moseley, G.B., 2007. Mission possible: managing innovation in drug discovery.

Nature biotechnology, Vol. 25, Issue 8, p. 945.

Contact Us